Isomorphic Labs has added Merck & Co. to its AI drug discovery partner roster days after raising $5 billion, extending a strategy that now reaches multiple top-revenue drugmakers rather than relying only on venture backing.

The new collaboration centers on discovering therapeutic small-molecule candidates against an oncology target that the companies described only as being of “strategic importance.” Financial terms include an upfront payment, plus research, development, regulatory and commercial milestones and tiered royalties. Isomorphic also has an option to co-fund development in return for elevated royalties.

Why This Deal Matters

For Isomorphic, the commercial signal is less about the undisclosed target than about partner concentration at the top end of pharma. Fierce Biotech reported that Merck joins Eli Lilly and Johnson & Johnson on Isomorphic’s disclosed partner list, and the company is also partnered with Novartis. In 2025, J&J, Lilly and Merck were the first, third and fourth largest drugmakers by revenue, respectively, meaning Isomorphic’s collaborator base now includes four of the top eight drugmakers.

That kind of partner mix suggests large companies are still willing to outsource selected early discovery work to AI-focused groups when they can pair modeling and compute capabilities with internal biology, data and development infrastructure. It also gives Isomorphic multiple shots at downstream economics through milestones, royalties and, in this case, a co-funding option.

The Operating Model

Merck said the collaboration will combine Isomorphic’s AI approach to discovery with the data and drug discovery experience of MSD Research Laboratories. George Addona, head of discovery, preclinical development and translational medicine at MSD Research Laboratories, said the key to using AI and machine learning successfully for molecular invention is close coordination of wet-lab and dry-lab functions.

That framing is notable because it positions AI as an accelerator inside existing discovery systems rather than a replacement for them. The value proposition here is faster and potentially better candidate design, but still tied to Merck’s internal data capabilities and discovery expertise.

The agreement also arrives just after investors put another $5 billion into Isomorphic, following a $2.1 billion commitment six months earlier. The latest Merck deal therefore reinforces that capital inflow with strategic validation from another large pharma company, a combination that can matter more than financing alone in AI drug discovery, where technical claims often outrun signed programs.